BR0202767A - Sistema de aplicação de droga bioadesivo - Google Patents

Sistema de aplicação de droga bioadesivo

Info

Publication number
BR0202767A
BR0202767A BR0202767-4A BR0202767A BR0202767A BR 0202767 A BR0202767 A BR 0202767A BR 0202767 A BR0202767 A BR 0202767A BR 0202767 A BR0202767 A BR 0202767A
Authority
BR
Brazil
Prior art keywords
delivery system
drug delivery
vaginal
therapeutically active
phase
Prior art date
Application number
BR0202767-4A
Other languages
English (en)
Inventor
Mitchell I Kirschner
R Saul Levinson
Thomas C Riley
Marc S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22282669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0202767(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of BR0202767A publication Critical patent/BR0202767A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"SISTEMA DE APLICAçãO DE DROGA BIOADESIVO". A presente invenção retere-se a um novo sistema de aplicação de droga vaginal de pH essencialmente neutro adequado para aplicação modificada de material terapeuticamente ativo na cavidade vaginal, o qual otimiza as chances para cura associada ao material terapeuticamente ativo. O sistema de aplicação de droga vaginal compreende uma emulsão de pH essencialmente neutro tendo glóbulos tendo duas fases, uma fase solúvel em água interna e uma fase insolúvel em água externa ou película, onde a fase interior solúvel em água contém uma droga ou drogas terapeuticamente ativa. Um novo aspecto do sistema de aplicação de droga: vaginal e que a fase solúvel em água interna compreende uma fase tamponada ácida.
BR0202767-4A 2002-03-20 2002-07-18 Sistema de aplicação de droga bioadesivo BR0202767A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/101,014 US6899890B2 (en) 2002-03-20 2002-03-20 Bioadhesive drug delivery system

Publications (1)

Publication Number Publication Date
BR0202767A true BR0202767A (pt) 2004-05-25

Family

ID=22282669

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0202767-4A BR0202767A (pt) 2002-03-20 2002-07-18 Sistema de aplicação de droga bioadesivo

Country Status (17)

Country Link
US (1) US6899890B2 (pt)
EP (1) EP1494630A4 (pt)
JP (1) JP4462818B2 (pt)
KR (2) KR20030076159A (pt)
CN (3) CN102048689A (pt)
AR (1) AR039037A1 (pt)
AU (2) AU2002300175B2 (pt)
BR (1) BR0202767A (pt)
CA (1) CA2392473C (pt)
FR (1) FR2837389A1 (pt)
HU (1) HUP0203102A3 (pt)
IT (1) ITMI20021660A1 (pt)
MX (1) MXPA02006943A (pt)
PT (1) PT102854B (pt)
RU (1) RU2320322C2 (pt)
WO (1) WO2003079981A2 (pt)
ZA (1) ZA200407535B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060732B2 (en) * 2000-12-12 2006-06-13 Imaginative Research Associates, Inc. Antibiotic/benzoyl peroxide dispenser
US20060189552A1 (en) * 2000-12-12 2006-08-24 Mohan Vishnupad Dispenser for dispensing three or more actives
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
US20050037033A1 (en) * 2003-05-23 2005-02-17 Program For Appropriate Technology In Health Microbicidal compositions and methods and use
ITTO20030404A1 (it) * 2003-05-30 2004-11-30 Rottapharm S R L Composizione per il ripristino dell'ecosistema vaginale
GB0315671D0 (en) * 2003-07-04 2003-08-13 Chelsea And Westminster Nhs Tr Improvements in or relating to organic compounds
WO2005027807A1 (en) * 2003-09-19 2005-03-31 Drugtech Corporation Pharmaceutical delivery system
US20060140990A1 (en) 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
EP2241326A1 (en) * 2003-12-08 2010-10-20 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
US8057433B2 (en) 2004-07-08 2011-11-15 Drugtech Corporation Delivery system
UA93354C2 (ru) * 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
US20060093675A1 (en) * 2004-10-29 2006-05-04 Mathew Ebmeier Intravaginal treatment of vaginal infections with metronidazole compositions
US7619008B2 (en) * 2004-11-12 2009-11-17 Kimberly-Clark Worldwide, Inc. Xylitol for treatment of vaginal infections
US20060217443A1 (en) * 2005-03-28 2006-09-28 Kimberly-Clark Worldwide, Inc. Method for preventing and/or treating vaginal and vulval infections
US20080193428A1 (en) 2005-04-27 2008-08-14 Shenzhen Phlora Biotechnology Limited Composition and Method for Modulating and Maintaining Vaginal Bacterial Flora and Vaginal Acidity
WO2006121429A1 (en) * 2005-05-06 2006-11-16 Imaginative Research Associates, Inc. Clindamycin compositions and delivery system therefor
EP1909752A2 (en) * 2005-05-09 2008-04-16 Drugtech Corporation Modified-release pharmaceutical compositions
US7786176B2 (en) * 2005-07-29 2010-08-31 Kimberly-Clark Worldwide, Inc. Vaginal treatment composition containing xylitol
EP1933810B1 (en) * 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
BRPI0614625A2 (pt) * 2005-08-12 2011-04-12 Drugtech Corp composição farmacêutica que compreende pelo menos um composto estrogênico, sistema de distribuição de estrogênio vaginal, uso de uma composição e kit que compreende uma pluralidade de cremes vaginais
AU2006332520A1 (en) * 2006-01-05 2007-07-12 Drugtech Corporation Drug delivery system for bioadhesion to a vulvovaginal surface
JP2009522360A (ja) * 2006-01-05 2009-06-11 ドラッグテック コーポレイション 組成物およびその使用方法
CA2641605A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
EP1872775A1 (en) * 2006-06-29 2008-01-02 Polichem S.A. Use of a hydrophilic matrix comprising a polyacrylic acid derivative, a cellulose ether and a disintegrant for the manufacture of a medicament for treating female genital disorders
WO2008005783A2 (en) * 2006-06-30 2008-01-10 Drugtech Corporation Treatment of non- infectious inflammatory vulvovaginitis with a bioadhesive clindamycin composition
US20080085877A1 (en) * 2006-08-10 2008-04-10 Drugtech Corporation Therapeutic methods of using estrogen compositions
US20080268022A1 (en) * 2007-02-23 2008-10-30 Mccabe R Tyler Mehtods for treating and preventing ailments caused by human papillomavirus
US20080287408A1 (en) * 2007-05-14 2008-11-20 Drugtech Corporation Endometriosis treatment
EP1994938A1 (en) * 2007-05-21 2008-11-26 Combinature Biopharm AG New lipoglycodepsipeptide compositions
ES2481454T3 (es) 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
US20090238867A1 (en) * 2007-12-13 2009-09-24 Scott Jenkins Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
JP5908279B2 (ja) 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 移植可能な薬物送達デバイス並びに男性の尿生殖器及び周囲組織を治療する方法
WO2010097344A1 (en) * 2009-02-26 2010-09-02 Basf Se Compositions, use and method for the use of surface active proteins in topical drug delivery across keratin
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
US20110008469A1 (en) * 2009-07-09 2011-01-13 Florida Gulf Coast University Antimicrobial composition and methods and apparatus for use thereof
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
EP2538929A4 (en) 2010-02-25 2014-07-09 Univ Johns Hopkins DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
RU2479305C2 (ru) * 2010-12-06 2013-04-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения инфекционных воспалительных заболеваний в гинекологии и способ ее получения
EP2663300B1 (en) 2011-01-10 2023-03-08 TARIS Biomedical LLC Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
WO2012137106A1 (en) 2011-04-04 2012-10-11 Environ Skin Care (Pty) Ltd The treatment of viral infections
KR20160112012A (ko) 2011-05-02 2016-09-27 아데어 파마슈티컬스 인코포레이티드 질내 투여용 속용성 정제 조성물
EP2757904B1 (en) * 2011-09-19 2017-01-11 OmniActive Health Technologies Limited An efficient process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption
US9180094B2 (en) 2011-10-12 2015-11-10 The Texas A&M University System High porosity materials, scaffolds, and method of making
RU2598627C2 (ru) * 2012-01-19 2016-09-27 Дзе Джонс Хопкинс Юниверсити Композиции на основе наночастиц с улучшенным проникновением через слизистые оболочки
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
RU2538703C2 (ru) * 2013-03-12 2015-01-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция для лечения вагинального кандидоза и способ ее получения
EP2968880B1 (en) 2013-03-15 2025-04-30 TARIS Biomedical LLC Drug delivery devices with drug-permeable component
WO2014192791A1 (ja) * 2013-05-30 2014-12-04 大正製薬株式会社 坐剤
HRP20201421T1 (hr) 2013-08-19 2020-12-11 Taris Biomedical Llc Uređaji za davanje više jedinica lijeka
WO2015070074A2 (en) 2013-11-08 2015-05-14 The Texas A &M University System Porous microparticles with high loading efficiencies
US20150238549A1 (en) * 2014-02-27 2015-08-27 Mak Wood, Inc. Probiotic dosage units
US10065029B2 (en) 2014-03-03 2018-09-04 Cook Medical Technologies Llc Mechanical dilator
US10335500B2 (en) 2014-05-12 2019-07-02 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
RU2017146425A (ru) 2015-05-29 2019-07-02 Ив Фарма Лтд. Pн-зависимые вагинальные композиции и способы лечения вагинальных нарушений
MX387286B (es) 2015-09-29 2025-03-18 Kimberly Clark Co Composicion sinergica para el mantenimiento de un equilibrio saludable de la microflora.
KR101880179B1 (ko) * 2016-11-03 2018-07-20 한국생명공학연구원 미카펀진(micafungin) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 항바이러스용 약학적 조성물
BR112019011015A2 (pt) * 2016-11-30 2019-10-08 Probioswiss Ag uso de uma composição, formulação e seu uso, lubrificante vaginal prebiótico e uso de uma cápsula vaginal simbiótica
GB2574534B (en) 2017-02-28 2022-06-08 Kimberly Clark Co Synergistic composition for maintenance of healthy balance of microflora
US20220047651A1 (en) * 2018-12-19 2022-02-17 Healthy Cow Corporation Ready-to-use probiotic compositions and uses thereof
WO2020210805A1 (en) 2019-04-11 2020-10-15 The Johns Hopkins University Nanoparticles for drug delivery to brain
US11529346B2 (en) * 2020-06-18 2022-12-20 National Medical Supply, LLC Vaginal gel

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3988508A (en) 1973-03-08 1976-10-26 Petrolite Corporation High internal phase ratio emulsion polymers
DE3321043A1 (de) * 1983-06-10 1984-12-13 Bayer Ag, 5090 Leverkusen Antimykotische mittel fuer einmalige gynaekologische behandlung
US4551148A (en) 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US5266329A (en) 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US4895452A (en) 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
CA1337279C (en) 1989-06-06 1995-10-10 Robert J. Borgman Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5298246A (en) 1991-01-09 1994-03-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Stable pharmaceutical composition and method for its production
ATE154241T1 (de) 1991-10-01 1997-06-15 Takeda Chemical Industries Ltd Mikropartikeln-zusammenfassung zur verlängerten freigabe und herstellung derselbe
US5189070A (en) 1992-05-29 1993-02-23 Shell Oil Company Process for preparing low density porous crosslinked polymeric materials
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US5470885A (en) 1993-09-29 1995-11-28 The Research Foundation Of The State University Of New York Fluorocarbons as anti-inflammatory agents
TW438601B (en) 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5980936A (en) 1997-08-07 1999-11-09 Alliance Pharmaceutical Corp. Multiple emulsions comprising a hydrophobic continuous phase
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system

Also Published As

Publication number Publication date
CA2392473C (en) 2007-09-18
KR20080098576A (ko) 2008-11-11
AU2003218233A1 (en) 2003-10-08
CN101045034A (zh) 2007-10-03
JP4462818B2 (ja) 2010-05-12
FR2837389A1 (fr) 2003-09-26
AR039037A1 (es) 2005-02-02
PT102854B (pt) 2004-02-27
RU2004130870A (ru) 2005-06-10
CA2392473A1 (en) 2003-09-20
HU0203102D0 (pt) 2002-11-28
CN1444926A (zh) 2003-10-01
CN102048689A (zh) 2011-05-11
AU2003218233A8 (en) 2003-10-08
KR20030076159A (ko) 2003-09-26
EP1494630A4 (en) 2007-03-14
ZA200407535B (en) 2006-06-28
ITMI20021660A1 (it) 2004-01-26
HUP0203102A3 (en) 2004-06-28
RU2320322C2 (ru) 2008-03-27
WO2003079981A3 (en) 2003-11-06
AU2002300175A1 (en) 2003-10-09
PT102854A (pt) 2003-09-30
US20030180366A1 (en) 2003-09-25
JP2003286193A (ja) 2003-10-07
US6899890B2 (en) 2005-05-31
MXPA02006943A (es) 2004-12-13
EP1494630A2 (en) 2005-01-12
WO2003079981A2 (en) 2003-10-02
HUP0203102A2 (hu) 2004-05-28
AU2002300175B2 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
BR0202767A (pt) Sistema de aplicação de droga bioadesivo
CA2105529C (en) Composition comprising non-steroidal anti-inflammatory agent and effectively non-antibacterial tetracycline
BR0207614A (pt) Preparação medicinal aderente à mucosa uso de uma preparação aderente à mucosa e processo para ministração de uma subst ncia farmaceuticamente ativa
BR9910066A (pt) Composição farmacêutica fluida que permite a liberação controlada de pelo menos uma substância ativa, processo de fabricação de uma composição farmacêutica, e, utilização de uma composição
BR0008058A (pt) Forma de estado sólido de celecoxib tendo biodisposnibilidade melhorada
BRPI0409345A (pt) sistema de liberação, pelìcula de sistema de liberação, e, processo para preparar o sistema de pelìcula de gel homogêneo
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
BG103552A (bg) Терапевтични средства
US4847290A (en) Delta 1-thc-7-oic acid and analgesic and anti-inflammatory agents
BR9807234A (pt) Composição farmacêutica
BRPI0009956A (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma
ES2149250T3 (es) Dispositivo para la administracion de medicamentos con liberacion controlada.
BRPI0410542A (pt) dispositivo de administração de medicamento para um olho e método de administrar um agente farmaceuticamente ativo a um olho
BR0016709A (pt) Agente antiadesão da flora patogênica da pele
BRPI0110914B8 (pt) 'composição farmacêutica líquida, processo para preparação da mesma e uso de uma composicão farmacêutica'
BR9914367A (pt) Composições contendo ácidos difosfÈnicos
CY1110078T1 (el) Παρασκευασματα με ιωδιουχο ποβιδονη για την αγωγη τραυματων
BR0116380A (pt) Método e composições que empregam formulaçoes de óleos de lecitina e fármacos antiinflamatórios não-esteróides (nsaids) para proteger o trato gastrointestinal e proporcionar maior atividade terapêutica
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
KR950703953A (ko) 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug)
ES2160821T3 (es) Uso de una composicion que comprende amoxicilina y acido clavulanico para la produccion de un medicamento para el tratamiento de infecciones bacterianas en pacientes pediatricos.
KR970032872A (ko) 아세틸살리실산을 함유하는 피부 손상 처치용 약물
BR0010983A (pt) Preparações para a aplicação de agentes antiinflamatórios

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2258 DE 15/04/2014.